Twenty diterpenoids were prepared for the evaluation of their antiproliferative potency on AR-positive prostate cancer cell models (LNCaP and 22Rv1) using AR-negative cell models (PC-3 and DU145) as comparisons. This evidence concerns the gene AR and prostate carcinoma.